Abstract
The burden of atherosclerosis is particularly high in western countries in terms of mortality and disability. The cerebral arteries (stroke or transient ischemic attack [TIA]), coronary arteries (myocardial infarction [MI]) and peripheral arteries (intermittent claudication [IC], ischemic limb) can be affected. Atherosclerosis may involve different mechanisms such as inflammation, platelet activation, endothelial damage, balance between proliferation and apoptosis of smooth muscle cells and oxidative stress. Research is focused to counteract each of these aspects. Many antithrombotic drugs are currently available and most of them act as inhibitors of platelet function. Aspirin, ticlopidine, clopidogrel and the combination of aspirin plus dipyridamole are widely used for primary (in high-risk patients) and secondary prevention of atherosclerotic diseases. Research of new pharmacological strategies is driven by the need to reduce the risk of bleeding associated with the use of antiplatelet drugs. In this context cilostazol, a type III phosphodiesterase inhibitor, has demonstrated antiplatelet and vasodilator effects with low rate of bleeding complications. This review will focus on the pharmacological properties of cilostazol and its use in the management of atherothrombotic vascular diseases.
Keywords: Atherosclerosis, antiplatelet agents, phosphodiesterase inhibitor, cilostazol, vascular prevention
Current Vascular Pharmacology
Title: Cilostazol in the Management of Atherosclerosis
Volume: 8 Issue: 3
Author(s): Fabrizio Sallustio, Federica Rotondo, Silvia Di Legge and Paolo Stanzione
Affiliation:
Keywords: Atherosclerosis, antiplatelet agents, phosphodiesterase inhibitor, cilostazol, vascular prevention
Abstract: The burden of atherosclerosis is particularly high in western countries in terms of mortality and disability. The cerebral arteries (stroke or transient ischemic attack [TIA]), coronary arteries (myocardial infarction [MI]) and peripheral arteries (intermittent claudication [IC], ischemic limb) can be affected. Atherosclerosis may involve different mechanisms such as inflammation, platelet activation, endothelial damage, balance between proliferation and apoptosis of smooth muscle cells and oxidative stress. Research is focused to counteract each of these aspects. Many antithrombotic drugs are currently available and most of them act as inhibitors of platelet function. Aspirin, ticlopidine, clopidogrel and the combination of aspirin plus dipyridamole are widely used for primary (in high-risk patients) and secondary prevention of atherosclerotic diseases. Research of new pharmacological strategies is driven by the need to reduce the risk of bleeding associated with the use of antiplatelet drugs. In this context cilostazol, a type III phosphodiesterase inhibitor, has demonstrated antiplatelet and vasodilator effects with low rate of bleeding complications. This review will focus on the pharmacological properties of cilostazol and its use in the management of atherothrombotic vascular diseases.
Export Options
About this article
Cite this article as:
Sallustio Fabrizio, Rotondo Federica, Di Legge Silvia and Stanzione Paolo, Cilostazol in the Management of Atherosclerosis, Current Vascular Pharmacology 2010; 8 (3) . https://dx.doi.org/10.2174/157016110791112331
DOI https://dx.doi.org/10.2174/157016110791112331 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
EDITORIAL: Different Aspects of Early Vascular Aging in Hypertension
Current Hypertension Reviews Advances in Antiplatelet Therapy for Stroke Prevention: the New P2Y12 antagonists
Current Drug Targets How to Keep Oxidative Stress Under Control?
Current Nutrition & Food Science Heart Disease Prediction System using Ensemble of Machine Learning Algorithms
Recent Patents on Engineering Biology and Clinical Relevance of Mannose-Binding Lectin
Drug Design Reviews - Online (Discontinued) Endothelin-1 Actions on Vascular Smooth Muscle Cell Functions As a Target for the Prevention of Atherosclerosis
Current Vascular Pharmacology Ocular Inflammatory Diseases: Molecular Pathogenesis and Immunotherapy
Current Molecular Medicine Exploring Old Drugs for the Treatment of Hematological Malignancies
Current Medicinal Chemistry Pathophysiological Basis for Anticoagulant and Antithrombotic Therapy in Pulmonary Hypertension
Cardiovascular & Hematological Agents in Medicinal Chemistry Treatment of Diabetic Foot Ulcer: An Overview Strategies for Clinical Approach
Current Diabetes Reviews Diet, Cardiometabolic Factors and Type-2 Diabetes Mellitus: The Role of Genetics
Current Diabetes Reviews Simvastatin: Review of Updates on Recent Trends in Pharmacokinetics, Pharmacodynamics, Drug–drug Interaction, Impurities and Analytical Methods
Current Pharmaceutical Analysis Structure Activity Relationship of 4-Amino-2-thiopyrimidine Derivatives as Platelet Aggregation Inhibitors
Medicinal Chemistry Pleuroparenchymal Fibroelastosis: Its Pathological Characteristics
Current Respiratory Medicine Reviews The Calcium-Sensing Receptor as a Regulator of Cellular Fate in Normal and Pathological Conditions
Current Molecular Medicine Effect of Local Paclitaxel Delivery Following Stenting on Restenosis andMorphology in the Porcine Coronary Artery
Vascular Disease Prevention (Discontinued) Advanced Glycation End Products (AGEs) and their Receptor (RAGE) System in Diabetic Retinopathy
Current Drug Discovery Technologies Hepatoma Derived Growth Factor is a Nuclear Targeted Mitogen
Current Drug Targets Role for Poly(ADP-ribose) Polymerase Activation in Diabetic Nephropathy, Neuropathy and Retinopathy
Current Vascular Pharmacology The Lung in Immune-Mediated Disorder: Rheumatoid Arthritis
Current Drug Targets - Inflammation & Allergy